logo
Secondary Progressive Multiple Sclerosis (SPMS) and Switching Treatments

Secondary Progressive Multiple Sclerosis (SPMS) and Switching Treatments

Health Line10-05-2025

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod.
There are four main types of multiple sclerosis (MS), with relapsing remitting MS (RRMS) being the most common.
However, some people who have RRMS may eventually develop secondary progressive multiple sclerosis (SPMS). SPMS features a steady decline in neurological function that can occur with or without relapses.
With SPMS, a relapsing-remitting disease pattern is still possible, though relapses may become less frequent. Neurological symptoms may also continue to decline as underlying nerve damage and neuron loss naturally worsen through age, stress, and other degenerative processes.
Like other presentations of MS, doctors treat SPMS using disease-modifying therapies (DMTs). In 2010, the drug fingolimod (Gilenya) became the first oral DMT approved by the Food and Drug Administration (FDA) for certain types of MS, including RRMS and SPMS.
Since then, advancements in MS treatment have continued to evolve. In particular, a new drug therapy called siponimod (Mayzent) was approved in 2019 specifically for use in SPMS. As a result, researchers have started to weigh the pros and cons of switching people who have SPMS from fingolimod to siponimod.
Reasons why you might want to switch treatments
According to a review from 2023, there are several reasons you may want to consider switching from fingolimod to siponimod for SPMS.
Specific approval from the FDA
Siponimod is specifically approved for treating SPMS, which is supported by clinical trial data.
Fingolimod is approved for relapsing forms of MS, which can include SPMS. However, the medication does not have significant clinical trial data focused specifically on SPMS.
Fewer side effects
Both siponimod and fingolimod are S1P receptor modulators. These drugs activate S1P receptors and prevent immune cells from attacking the myelin sheath around nerves.
However, siponimod is more selective than fingolimod when it comes to which S1P receptors it targets. This helps reduce the risk of side effects.
Less intensive monitoring
The broad S1P action of fingolimod means the drug is associated with certain risks, particularly:
slowed heart rate (bradycardia)
liver damage
eye swelling
increased infection risk
When you're prescribed fingolimod, the first dose is given under medical supervision, and heart monitoring is required for 6 hours afterward. If no problems are detected, you can continue to take the medication on your own at home. But you'll need to work with your doctor to set a schedule for ongoing routine monitoring.
Siponimod appears to have a lower risk of heart-related side effects due to its more targeted mechanism of action. As a result, it requires less strict monitoring. However, you still need to work with your doctor to discuss how often to schedule checkups to monitor how well the medication is working.
Shorter washout time
Siponimod has a shorter half-life (30 hours) than fingolimod (6 to 9 days). A shorter half-life suggests it may clear from your system faster.
Better remyelination
Siponimod targets specific S1P receptor subtypes, particularly S1P5, which is involved in myelin-producing cell survival and function. Myelin is the protective layer around the nerves that can become inflamed and damaged in MS.
As a result, research suggests that this targeted approach that siponimod provides may offer enhanced repair of myelin (remyelination) effects compared with the broad S1P action of fingolimod.
Factors to consider when switching
Not everyone may benefit from switching from fingolimod to siponimod.
If your SPMS is well managed on fingolimod and you're not experiencing significant side effects, there's no guarantee your MS will do better on siponimod. Switching off an effective treatment isn't always recommended just because a new medication might offer some benefits.
Switching off fingolimod has also been associated with certain risks, like disease reactivation, in some people. When you switch from fingolimod to a more targeted drug like siponimod, experts believe your inflammatory response may become upregulated, which can promote active disease.
Another consideration before switching from fingolimod to siponimod is genetic testing. Siponimod is not recommended for use in people who have certain variants of the CYP2C9 gene, which slow siponimod metabolism and can increase the risk of side effects.
Switching from fingolimod to siponimod
Clinical trial data on siponimod suggests most people can immediately switch to it from fingolimod with no major side effects or reactions.
Before you make the switch, your doctor will order genetic screening to check for known CYP2C9 variants.
If your results indicate you're a candidate for siponimod, the next step is to discontinue your current DMT. Some DMTs, like teriflunomide (Aubagio), may require a washout period where you have to wait for the medication to fully clear from your system before starting siponimod.
Even though siponimod has more favorable safety parameters than fingolimod, it can still cause the same types of side effects. Before starting siponimod, a cardiac evaluation, blood screening, eye exam, and skin exam are all recommended to ensure no underlying conditions might increase your risk.
Other disease-modifying therapies for SPMS
In addition to fingolimod and siponimod, FDA-approved DMTs used in the treatment of SPMS include:
ocrelizumab (Ocrevus)
mitoxantrone (Novantrone)
Additional DMTs for SPMS are in development and in clinical trials. In December 2024, the FDA granted the designation of 'breakthrough therapy' to the drug tolebrutinib for use in non-remitting SPMS. Tolebrutinib belongs to a class of medications called Bruton's tyrosine kinase (BTK) inhibitors.
Other BTK inhibitors being investigated for use in MS include:
orelabrutinib
fenebrutinib
BIIB091
Talking with your healthcare team
SPMS is a complex condition that affects each person differently. Finding the right combination of medication and supportive therapies often requires trial and error.
Switching from fingolimod to siponimod starts with a conversation with your healthcare team. Discuss with your doctor why you want to switch medications, and come prepared with a list of your questions and concerns.
Questions you may want to ask your doctor include:
Do you recommend switching from fingolimod to siponimod?
How will siponimod change my treatment plan?
What tests do I need to have done?
Am I at an increased risk of certain side effects?
Is there a washout period?
Do any of my other medications prevent me from taking siponimod?
How will I know if the treatment is effective? How soon?
What happens if I miss a dose?
What should I expect from the first few weeks of treatment?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CVD Mortality Higher in Women With Inflammatory Diseases
CVD Mortality Higher in Women With Inflammatory Diseases

Medscape

time36 minutes ago

  • Medscape

CVD Mortality Higher in Women With Inflammatory Diseases

Although cardiovascular disease (CVD)-related mortality decreased significantly from 1999 to 2020 in both men and women with immune-mediated inflammatory diseases (IMIDs), women consistently had higher rates of CVD-related mortality than men over the 22-year period. METHODOLOGY: Researchers analyzed CDC Multiple Cause of Death files from 1999 to 2020 to assess the sex differences in CVD-related mortality in patients with IMIDs. They identified CVD-related deaths with underlying IMIDs in the United States using diagnostic codes. IMIDs such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis were analyzed. The analysis included 281,355 IMID-related deaths and 127,149 CVD-related deaths over a period of 22 years. Annual crude and adjusted death rates were estimated. TAKEAWAY: Age-adjusted CVD-related mortality for women with IMIDs declined from 3.3 per 100,000 in 1999 to 1.4 per 100,000 in 2020, whereas the rate in men with IMIDs declined from 2.3 to 1.1 per 100,000 ( P < .01). < .01). However, women had higher mortality than men throughout the study duration (mortality rate ratio, 1.5; P < .01). < .01). Cerebrovascular disease and ischemic heart disease were major causes of death, with women more affected than men; women experienced mortality from arrhythmia and cardiac arrest at more than twice the rate of men. Among patients with IMIDs, women with rheumatoid arthritis had disproportionately higher crude CVD-related mortality than men with rheumatoid arthritis. IN PRACTICE: 'Addressing these risks requires increasing awareness of atypical cardiovascular symptoms in females with IMIDs, enhancing early detection through advanced imaging, and ensuring equitable access to therapies like biologics,' the study authors wrote. SOURCE: This study was led by Issam Motairek, MD, Cleveland Clinic, Cleveland. It was published online on May 5, 2025, in Circulation: Cardiovascular Quality and Outcomes . LIMITATIONS: The potential inaccuracies in the codes for identifying the cause of death may have misclassified IMIDs or CVD-related causes. The aggregate data structure prevented the analyses of individual-level factors such as severity of disease or treatments. Less common IMIDs were excluded, which may have underestimated their contribution to CVD. DISCLOSURES: This study received no specific funding. The authors reported having no conflicts of interest.

JPD's co-responder unit saves $950K yearly with new approach
JPD's co-responder unit saves $950K yearly with new approach

Yahoo

time41 minutes ago

  • Yahoo

JPD's co-responder unit saves $950K yearly with new approach

JOPLIN, Mo. — The Joplin City Council learns about early successes of a new program at the police department. It's called the Joplin Police Department Co-Responder Unit or CRU. The program started back in October. The goal is to address social and behavioral health concerns, and to separate those dealing with a crisis and those committing an actual crime. During a work session Monday (6/9), council heard a presentation by Joplin Police Chief, Dr. Richard Pearson and others, regarding the success of the CRU program. CRU now has three full-time employees, thanks to a partnership with Ozark Center. It's expected to save at least $950,000 annually, through reduced hospitalizations, decreased jail bookings, and time saved by police officers who can now focus their efforts on issues involving crime. 'If we can keep a person from being homeless, if we can keep that person from being in the emergency room, if we can get that person housed, if we can get that person back up and running and becoming a productive member of society again, instead of that person committing crimes,' said Dr. Pearson. 'You know, two groups of people who can't say no are those who run ERs and those who have a jail. So, it's incredibly important that we're able to show that not only are we doing the right thing and that we can feel good as a community about doing the right thing, but that it's also fiscally responsible,' said Ozark Center Chief Clinical Officer, Del Camp. The JPD Co-Responder Unit is currently operating on grant funding. However, following Monday's presentation, council directed city staff to find room in the budget to keep the program operating and growing. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Modesto school district's proposed "Puberty Talk" curriculum raises concerns
Modesto school district's proposed "Puberty Talk" curriculum raises concerns

CBS News

timean hour ago

  • CBS News

Modesto school district's proposed "Puberty Talk" curriculum raises concerns

A controversy is brewing in Modesto as the local school district is considering adopting a new health curriculum called "Puberty Talk" for 5th graders. There's growing pushback not just from parents but from one of the district's board members over what the children should or shouldn't be learning about sex and gender. But Modesto City Schools says this is not sex education. It is health education. School board member Jolene Daly says the plan dives too deep into matters that are too adult for children. She's a licensed family therapist who says the lessons could cause students psychological harm. "They're not really understanding the psychological impact of some of the statements that are being made on the cognitive develop of the of these young kids," she said. CBS13 reviewed the material at the district's office. It includes chapters titled "Consent Plus Boundaries," "Identity Plus Expression" and "Puberty Health and Hygiene," which include discussions about different kinds of intercourse. "The hygiene portion of it tells them to make sure that they wash their hands and their genitals," Daly told CBS Sacramento over Zoom. "These 10 and 11-year-olds don't have the capacity to understand some of the information that is in the text." The district says the curriculum meets state requirements under the California Healthy Youth Act and that parents can opt out. But one mother of a student argues these are discussions that need to be had. "I think it's important to talk about it before those changes happen," the mother said. "I think normalizing things makes it better." The board took public comment on the material Monday night, and parents were able to see the material for themselves at the district's professional development building They'll vote on this matter on June 28.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store